echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Two new class 1 drugs of Haisco have entered the new field and new indications of innovative drugs in anesthesia are here

    Two new class 1 drugs of Haisco have entered the new field and new indications of innovative drugs in anesthesia are here

    • Last Update: 2022-03-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 8th, the good news of Hisco's innovative drugs continued: Class 1 new drugs HSK31858 tablets and HSK31679 tablets were approved for clinical use, and the new drug clinical application for HSK36212 capsules was also undertaken by CDE; in addition, the company's cyclopofol injection, which was approved for marketing in 2020 The listing application for the sixth indication of the liquid has also been accepted.


    Table 1: Hisco's Class 1 new drugs for clinical application in 2021

    Source: CDE official website, Minet database

    In 2021, Hisco has submitted a total of 5 clinical applications for Class 1 new drugs, all of which have been approved for clinical use so far


    HSK29116 powder is an oral Protac small molecule anti-tumor drug.


    The HSK31679 tablets and HSK31858 tablets approved for clinical use this time are both products declared for the first time


    Figure 1: Hisco's latest clinical application of Class 1 new drugs

    Source: CDE official website

    In January 2022, Haisco submitted a new drug clinical application for HSK36273 for injection, which is currently under review and approval.


    Table 2: Reported production situation of Haisco Cyclopofol Injection

    Source: MED2.


    On February 8, Haisco issued an announcement stating that the application for listing of Cyclopofol Injection for the indication of "sedation and anesthesia for gynecological outpatient surgery" has been accepted


    Judging from the current situation, Haisco's innovative drugs maintain a positive trend of "approval and application" every year.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.